BofA raised the firm’s price target on Tempus AI (TEM) to $60 from $54 and keeps a Neutral rating on the shares after the company reported Q4 ...

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade ...

ARK Invest's 2,300 BTC acquisition worth $196.26M signals rising institutional confidence, reinforcing Bitcoin’s growing role ...

Eric Lefkofsky, CEO and founder of Tempus AI, explains to Scottish Mortgage manager Tom Slater the huge potential in personalising cancer diagnosis and treatment at scale. Capital at risk.

Tempus AI (NASDAQ: TEM) is utilizing artificial intelligence to deliver better healthcare outcomes. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was up 12.7% on Wednesday after Needham & Company LLC raised their price target on the stock from $56.00 to $70.00. Needham & Company LLC currently has a ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Tempus AI (NASDAQ:TEM – Get Free Report) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...